About o2h Theraputics EIS Fund

The o2h Therapeutics EIS fund provides investors with the opportunity to invest in the growth potential of UK life science and AI. It has created an integrated model for supporting investee companies. This includes offering these companies a base at its headquarters, recognising that early-stage businesses often require more than funding to succeed.

The minimum subscription is £25,000 and portfolio size is around five-10 companies. The expected exit timescale is within three-seven years.

o2h Theraputics EIS Fund Summary

Fund Manager: o2h Ventures
Tax Efficiency: EIS and SEIS
Sector Focus: Biotech, Medtech, and Pharma
Stage Focus: Early-stage
Target Portfolio Size: 5 - 10 companies
Minimum Subscription: £25,000
Closing Date: Evergreen
Website: Learn more about o2h Theraputics EIS Fund

About o2h

Cambridge-based o2h invests in emerging life-science and technology companies, including those specialising in biotech, digital health and software. The company has an emerging portfolio of seed-stage investments in ‘frontier’ technology companies. Its managing partners are Sunil Shah, who was joint winner of the UK Business Angels Association’s angel of the year award in 2019, and his brother Prashant Shah. To date, they have invested in around 20 biotech companies, mainly in the Cambridge area.

Contact o2h

Please note: SyndicateRoom is not affiliated with o2h Theraputics EIS Fund. This page is for informational purposes only, and is the result of research conducted by SyndicateRoom. Whilst every effort has been taken to ensure accuracy at the time of publication this cannot be guaranteed and information is liable to change. Information displayed is neither a recommendation to invest or not, nor advice. With investments, your capital is at risk. SyndicateRoom is not responsible for the content of any external websites linked to from this page.

Are you the fund manager? Email [email protected] with any comments or amends.